chemotherapy

Three improvements data promises to deliverPersonalized, prescriptive medicine creates higher-value care for patients
Ocular surface tumors require careful exam, consideration of best options
Ocular surface tumors require careful exam, consideration of best optionsAlthough surgery is still the gold standard for ocular surface tumors, consider the pros and cons of topical chemotherapy as appropriate.
Selective techniques revolutionize treatment for retinoblastomaAdvancements in retinoblastoma have occurred in the areas of treatment, genetic testing, and diagnostic imaging.
Immuno-oncology bladder drug wins approvalSoon after approving the same drug for metastatic Merkel cell carcinoma, FDA approved immuno-oncology avelumab (Bavencio) for locally advanced or metastatic urothelial carcinoma.
Predictive analytics reduces chemotherapy-associated hospitalizationsPatient risk can improve value-based cancer care. Find out how.
Aggressive price growth pushes healthcare spending upRise in use of outpatient care and professional services contributed to quicker growth in spending for the privately insured over previous years.
Biomarkers: Top challenges and opportunities in managed careBiomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.
FDA approves trifluridine/tipiracil for colorectal cancerLonsurf is a new, orally administered cytotoxic drug for the treatment of patients with metastatic colorectal cancer.
FDA approves rolapitant to prevent chemotherapy-induced nausea and vomitingRolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.
Experts debate best treatment for metastatic colorectal cancer patientsDe-escalated maintenance or “drug holidays”: What’s best for patients with metastatic colorectal cancer?